After-Hours Stock Movers 02/06: (ASRT) (PINS) (UBER) Higher; (ZGNX) (MYGN) (RESN) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: Wells Fargo Upgrades IntercontinentalExchange (ICE) to Overweight, 'Don't Waste a Good Crisis'
February 10, 2020 5:50 AM EST(Updated - February 10, 2020 6:05 AM EST)
(updating comment)
Wells Fargo analyst Christopher Harris upgraded IntercontinentalExchange (NYSE: ICE) from Equal Weight to Overweight with a price target of $105.00.
The analyst comments "We think the decline in ICEs stock price since... More
Corbus Pharma (CRBP) Prices 6.67M Share Common Offering at $6/Sh
February 7, 2020 9:03 AM ESTCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $6.00 per share, for a total public offering size of approximately $40 million, before deducting underwriting discounts and estimated offering... More
UPDATE: MKM Partners Upgrades Uber Inc. (UBER) to Buy
February 7, 2020 7:45 AM EST(Updated - February 7, 2020 9:15 AM EST)
(updated to add analyst comments)
MKM Partners analyst Rohit Kulkarni upgraded Uber Inc. (NYSE: UBER) from Neutral to Buy with a price target of $45 (from $34).
The analyst commented, "Uber reported a somewhat mixed quarterly result with Bookings, Take Rate, Revenue, and Adj. EBITDA coming in above... More
Uber Inc. (UBER) PT Raised to $49 at Goldman Sachs
February 7, 2020 7:20 AM ESTGoldman Sachs analyst Heath Terry raised the price target on Uber Inc. (NYSE: UBER) to $49.00 (from $44.00) while maintaining a Buy rating.
... MoreUber Inc. (UBER) PT Raised to $52 at Wedbush
February 7, 2020 7:19 AM ESTWedbush analyst Ygal Arounian raised the price target on Uber Inc. (NYSE: UBER) to $52.00 (from $50.00) while maintaining a Outperform rating.
... MoreUber Inc. (UBER) PT Raised to $56 at Needham & Company
February 7, 2020 7:15 AM ESTNeedham & Company analyst Brad Erickson raised the price target on Uber Inc. (NYSE: UBER) to $56.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "UBER's report highlighted continued strong execution and while the top-line guidance was a little light of expectations, meaningfully better... More
Pinterest Inc (PINS) PT Raised to $26 at Rosenblatt
February 7, 2020 6:56 AM ESTRosenblatt analyst Mark Zgutowicz raised the price target on Pinterest Inc (NYSE: PINS) to $26.00 (from $23.00) while maintaining a Neutral rating.
... MoreUber Inc. (UBER) PT Lowered to $59 at RBC Capital
February 7, 2020 6:21 AM ESTRBC Capital analyst Mark Mahaney lowered the price target on Uber Inc. (NYSE: UBER) to $59.00 (from $64.00) while maintaining an Outperform rating.
The analyst commented, "Uber reported Strong Q4 results, w/ Bookings, Net Revenue & EBITDA all solidly above RBC/Street. Rides segment revealed significant... More
ADMA Biologics (ADMA) Prices 23.5M Share Upsized Common Offering at $3.50/Sh
February 7, 2020 6:10 AM ESTADMA Biologics, Inc. (NASDAQ: ADMA) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced the pricing of its previously announced underwritten public offering of 23,500,000 shares... More
ADMA Biologics (ADMA) Announces Proposed $75M Share Common Offering
February 7, 2020 6:09 AM ESTADMA Biologics, Inc. (NASDAQ: ADMA) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced that it has commenced an $75 million underwritten public offering of... More
UPDATE: William Blair Upgrades 2U, Inc. (TWOU) to Outperform; 'Turning the Corner'
February 7, 2020 4:15 AM EST(Updated - February 7, 2020 7:33 AM EST)
(updated to add analyst comments)
William Blair analyst Stephen Sheldon upgraded 2U, Inc. (NASDAQ: TWOU) from Market Perform to Outperform.
The analyst commented, "s. We are incrementally encouraged by results and commentary this quarter, including... More

